At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09887 LEADS BIOLABS-B
Not Yet Opened 10-15 16:08:35
40.660
-1.280
-3.05%
High42.320Low40.100Vol1.33M
Open42.000D1 Closing41.940Amplitude5.29%
Mkt Cap8.09BTradable Cap8.05BTotal Shares199.00M
T/O54.50MT/O Rate0.67%Tradable Shares198.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Leads Biolabs Says FDA Grants Fast Track Status to Opamtistomig for First-Line Biliary Tract Cancer
Reuters  ·  10-12
Leads Biolabs Says FDA Grants Fast Track Status to Opamtistomig for First-Line Biliary Tract Cancer
Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
THOMSON REUTERS  ·  10-12
Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
Nanjing Leads Biolabs Says FDA Grants Fast Track Designation to LBL-024
Reuters  ·  10-12
Nanjing Leads Biolabs Says FDA Grants Fast Track Designation to LBL-024
Nanjing Leads Biolabs Co - FDA Grants Fast Track Designation to Lbl-024 for First-Line Advanced Biliary Tract Cancer
THOMSON REUTERS  ·  10-12
Nanjing Leads Biolabs Co - FDA Grants Fast Track Designation to Lbl-024 for First-Line Advanced Biliary Tract Cancer
Why Nanjing Leads Biolabs (SEHK:9887) Is Getting Attention Today
Simply Wall St.  ·  10-09
Why Nanjing Leads Biolabs (SEHK:9887) Is Getting Attention Today
Movement Alert｜LEADS BIOLABS-B Falls 5.24% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure
Market Focus  ·  10-02
Movement Alert｜LEADS BIOLABS-B Falls 5.24% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure
LEADS BIOLABS-B (09887) Shares Rise Over 2% as Core Product Vilixin Secures Orphan Drug Designation in Japan
Stock News  ·  09-30
LEADS BIOLABS-B (09887) Shares Rise Over 2% as Core Product Vilixin Secures Orphan Drug Designation in Japan
Hong Kong Stock Announcements: Four New Listings Debut Today Including Robotechnik and Kinwong; GAC Group Plans A-Share Issuance to Acquire 50% Stake in GAC Toyota
Stock News  ·  09-29
Hong Kong Stock Announcements: Four New Listings Debut Today Including Robotechnik and Kinwong; GAC Group Plans A-Share Issuance to Acquire 50% Stake in GAC Toyota
Hong Kong Stocks Rise as ETF Listings Boost Sentiment; Biolabs Falls 4%
MT Newswires Live  ·  09-28
Hong Kong Stocks Rise as ETF Listings Boost Sentiment; Biolabs Falls 4%
Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Opamtistomig (Lbl-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
THOMSON REUTERS  ·  09-28
Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Opamtistomig (Lbl-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
Nanjing Leads Biolabs' Cancer Therapy Gets Orphan Drug Status in Japan; Shares Fall 5%
MT Newswires Live  ·  09-28
Nanjing Leads Biolabs' Cancer Therapy Gets Orphan Drug Status in Japan; Shares Fall 5%
LEADS BIOLABS-B (09887) Core Product VELIXIN Receives Orphan Drug Designation in Japan
Stock News  ·  09-28
LEADS BIOLABS-B (09887) Core Product VELIXIN Receives Orphan Drug Designation in Japan
Nanjing Leads Biolabs Co - Lbl-024 Granted Orphan Drug Designation by Mhlw in Japan for Ep-Nec
THOMSON REUTERS  ·  09-28
Nanjing Leads Biolabs Co - Lbl-024 Granted Orphan Drug Designation by Mhlw in Japan for Ep-Nec
Is LEADS BIOLABS-B (09887), in a Sustained One-Way Decline, Getting Closer to a Key Turning Point for Its Next Move?
Stock News  ·  09-26
Is LEADS BIOLABS-B (09887), in a Sustained One-Way Decline, Getting Closer to a Key Turning Point for Its Next Move?
Movement Alert｜LEADS BIOLABS-B Falls 5.6% in Regular Trading, Biotech Sector Weakness Compounds Post-Volatility Profit-Taking
Market Focus  ·  09-24
Movement Alert｜LEADS BIOLABS-B Falls 5.6% in Regular Trading, Biotech Sector Weakness Compounds Post-Volatility Profit-Taking
LEADS BIOLABS-B Posts Wider Interim Loss as NDA for Core Asset LBL-024 Enters Priority Review
Bulletin Express  ·  09-23
LEADS BIOLABS-B Posts Wider Interim Loss as NDA for Core Asset LBL-024 Enters Priority Review
Movement Alert｜LEADS BIOLABS-B Rises 5.54% in Regular Trading, ESMO Late-Breaking Abstract Selection Drives Rebound After Prior Session Sell-Off
Market Focus  ·  09-23
Movement Alert｜LEADS BIOLABS-B Rises 5.54% in Regular Trading, ESMO Late-Breaking Abstract Selection Drives Rebound After Prior Session Sell-Off
Nanjing Leads Biolabs to Present Rare Lung Cancer Study Papers at 2026 ESMO; Shares Fall 3%
MT Newswires Live  ·  09-22
Nanjing Leads Biolabs to Present Rare Lung Cancer Study Papers at 2026 ESMO; Shares Fall 3%
Movement Alert｜LEADS BIOLABS-B Falls 5.59% in Regular Trading, Profit-Taking and Incentive Platform Stake Reduction Weigh on Shares Despite Positive ESMO Data
Market Focus  ·  09-22
Movement Alert｜LEADS BIOLABS-B Falls 5.59% in Regular Trading, Profit-Taking and Incentive Platform Stake Reduction Weigh on Shares Despite Positive ESMO Data
Leads Biolabs Submits China NDA for Opamtistomig in Advanced EP-NEC
Reuters  ·  09-22
Leads Biolabs Submits China NDA for Opamtistomig in Advanced EP-NEC

Introduction

Company Name.
LEADS BIOLABS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Nanjing Leads Biolabs Co Ltd is a China-based company primarily engaged in the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The company's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The Company has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The Company mainly conducts its business in the domestic market.
Issue price:
--